Center for Chronic Intestinal Failure, Department of Gastroenterology and Internal Medicine, St. Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
Clin Nutr. 2012 Dec;31(6):831-45. doi: 10.1016/j.clnu.2012.05.004. Epub 2012 Jun 2.
BACKGROUND & AIMS: Indications and timing for referral for intestinal transplantation (ITx) were investigated through a review of the literature on home parenteral nutrition (HPN) for benign intestinal failure and a benchmarking to the results of a prospective European survey which evaluated the appropriateness of the current indications for ITx.
Manuscripts reporting outcomes of adults and children on HPN were retrieved through a PubMed search. Data from the European survey were compared with those on HPN reported in the literature, and with those on ITx reported by the USA registry and by the Pittsburgh center.
HPN is a safe treatment with a high probability of survival. The risk of death during HPN is increased by the absence of a specialist team, and appears greater during the early period of treatment. Survival probability is decreased in patients with: age >40 or <2 years, very short bowel remnant, presence of a stoma, chronic intestinal pseudo-obstruction of myopathic origin, systemic sclerosis, radiation enteritis, intra-abdominal desmoids, necrotizing enterocolitis, congenital mucosal diseases. Liver failure is the HPN-related complication with the greatest risk of death. Death related to venous catheter complications is rare. The benchmarking supported the results of the European survey.
通过回顾有关肠外营养(HPN)治疗良性肠道衰竭的文献,并与评估当前肠移植(ITx)适应证的前瞻性欧洲调查结果进行基准比较,研究了 ITx 的适应证和转介时机。
通过 PubMed 搜索检索报告接受 HPN 的成人和儿童结局的文献。将欧洲调查的数据与文献中报告的 HPN 数据以及美国登记处和匹兹堡中心报告的 ITx 数据进行比较。
HPN 是一种安全的治疗方法,具有较高的生存率。缺乏专业团队会增加 HPN 期间的死亡风险,并且在治疗的早期阶段似乎更大。生存率降低的患者包括:年龄>40 岁或<2 岁、短肠残留非常短、存在造口、肌源性慢性假性肠梗阻、系统性硬化症、放射性肠炎、腹腔内纤维瘤、坏死性小肠结肠炎、先天性黏膜疾病。肝功能衰竭是 HPN 相关并发症中死亡率最高的。与静脉导管并发症相关的死亡很少见。基准比较支持欧洲调查的结果。